Indoco Remedies Q2 Review - Reaffirmed Its Guidance For FY22: Systematix
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
Indoco Remedies Ltd.'s Q2 FY22 earnings missed our estimates as European business was hit by shipment delays due to unavailability of containers/certain active pharma ingredient’s and profit share from Brinzolamide is not fully realised yet in the U.S.
Management maintained its guidance for U.S./Europe implying a sharp pick-up in H2.
India business is on track to deliver Rs 8 billion plus revenues, in line with management guidance.
Underlying trends remain strong and Indoco Remedies is on track to deliver a 55% earnings per share compound annual growth rate over FY21-23E.
We tweak our estimates to build in Q2 earnings, which leads to a 3%/6% cut in FY22/FY23 earnings.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.